



Proteomics International

LABORATORIES LTD

ASX/Media Release

13 September 2019

ASX code: PIQ

PromarkerD launched in Spain

Highlights

- **Proteomics International has officially launched PromarkerD in Spain under a deal with Patia Europe**
- **The PromarkerD test system is the first test globally that is capable of predicting the onset of diabetic kidney disease**
- **The exclusive licence agreement with Patia Europe for Spain is for two years and Proteomics International will receive a royalty on each test sold**
- **The launch coincides with PromarkerD being showcased at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, 16-20 September 2019**
- **The launch is a pivotal milestone for Proteomics International, providing a platform to broaden awareness of PromarkerD, potentially accelerating the execution of additional licensing transactions**

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) announces it has officially launched the company's world-leading predictive diagnostic test for diabetic kidney disease, PromarkerD, in Spain.

The European launch of PromarkerD is a pivotal milestone for Proteomics International providing a critical market platform to broaden the awareness of the test, potentially accelerating the execution of additional licensing transactions and jurisdictional launches.

PromarkerD is being commercialised by Patia Europe [ASX: 24 October 2018], with the Laboratory Developed Test (LDT) being offered through an expansion of the partnership with specialist mass spectrometry diagnostics firm Atturos, Ireland [ASX: 12 September 2019]. The exclusive licence agreement with Patia Europe for Spain is for two years and Proteomics International will receive a royalty on each test sold.

Currently in Spain, diabetes affects 10 per cent of the adult population—or 3.6 million people. Like the rest of Europe, the incidence of diabetes is increasing rapidly. Across the whole European region there are more than 58 million people with diabetes, and that is expected to rise to 67 million people by 2045. An estimated one in three adults with diabetes already have chronic kidney disease, however, with early intervention it is possible to delay or prevent clinical symptoms of the disease.

PromarkerD is a simple blood test that uses a unique protein 'fingerprint' to provide an early detection of diabetic kidney disease. PromarkerD is the first test able to predict the onset of diabetic kidney disease, warning of a decline in kidney function up to four years in advance.

Proteomics International Managing Director Dr Richard Lipscombe said that, "as the first country in Europe to adopt the PromarkerD test, Spain would be at the forefront of diabetic kidney disease diagnosis and prevention."

Patia Europe CEO Dr Laureano Simon said the predictive powers of PromarkerD would improve the lives of people with diabetes in Spain. "This world-first technology will allow doctors to intervene

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

early and prescribe treatments to prevent patients from developing diabetic kidney disease. It's a huge step towards addressing one of the most costly complications of the diabetes crisis," he said.

The announcement coincides with PromarkerD being showcased at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, 16-20 September 2019 where Patia Europe and Proteomics International are meeting with diagnostic and pharmaceutical companies and Key Opinion Leaders from around the world to expand the global reach of PromarkerD.

Proteomics International is in discussions with tier-1 diagnostics and pharmaceutical companies, targeting the markets of Europe, Japan, India and US, to expand the global reach of PromarkerD.

ENDS

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
[Corporate Advisor & Investor Relations]
Adelaide Equity Partners
T: +61 8 8232 8800
E: dvandissel@adelaideequity.com.au

Dr Laureano Simon
Chief Executive Officer
Patia Europe
T: +34 678531361
E: lsimon@patiadiabetes.com

About PromarkerD (www.PromarkerD.com)

The PromarkerD test system assesses the risk of diabetic kidney disease in patients with type 2 diabetes. Chronic kidney disease is one of the major complications arising from diabetes and if unchecked can lead to dialysis or kidney transplant. PromarkerD is a simple blood test that uses a unique protein 'fingerprint' to provide an early detection of the onset of disease. In clinical studies published in leading journals PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. PromarkerD has received patent protection in multiple jurisdictions including Europe, China, Japan and the USA.

Further information is available through the PromarkerD web portal.

About Patia Europe (www.patiadiabetes.com/en)

Patia Europe is established in Spain as a subsidiary company of Patia Biopharma Mexico. Patia is a public health company that integrates genomic, proteomic and metabolomic tools, with digital applications, to prevent and manage type 2 diabetes and gestational diabetes.

Patia is part of the SIGMA project, carried out at the Broad Institute of Harvard University and MIT, located in Cambridge, Massachusetts, US, which set out to identify genetic risk factors for diabetes. Analysis has discovered new genetic variations that are associated with type 2 diabetes, and Patia is now translating this knowledge into clinical devices to improve treatment of the disease.

About Atturos (www.atturos.com)

Atturos Ltd (Dublin, Ireland) is a privately funded clinical diagnostics company developing and commercialising advanced molecular diagnostics solutions to enable clinicians and patients make better healthcare decisions. A University College Dublin spin out company, Atturos was founded initially to commercialise the OCPProDx test, a pioneering blood test that can determine whether diagnosed prostate cancer is confined to the prostate or has spread beyond it. The company is

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

actively expanding its portfolio of advanced diagnostic solutions that address areas of significant clinical need.

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world’s first ISO 17025 laboratory accreditation for proteomics services and operates from state-of-the-art facilities located on Perth’s QEII Medical Campus. The Company’s business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.